ArticleFrontiers in oncology2023

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.

Agnese Fabbri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.